Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SII Variant Vaccines for COVID-19
NCT05029856Phase 2Withdrawn
- Sponsor
- Novavax
- Start
- Feb 2022
- Primary completion
- Aug 2022
- Modality
- Nanoparticles, Recombinant Proteins and Enzymes, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of SII B.1.351, SII B.1.617.2, SII Bivalent in coronavirus disease 2019 (COVID-19), sponsored by Novavax. Planned start Feb 2022; status: withdrawn.
02
Drugs
SII B.1.351SII B.1.617.2SII Bivalent
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05029856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05029856.